Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VPHM - Viropharma Inc -- Ignore unavailable to you. Want to Upgrade?

To: CoffeePot who wrote (134)	7/14/1999 8:16:00 PM
From: Anthony@Pacific	Respond to of 2557

VPHM<--------NO BUYERS ANYWHERE ON YAHOO< RAGING BULL< SI--> Or anywhere else..They have all realized that they have been hyped into another momentum nonevent.......Lets go one step further.....Who is going to buy this stock and hold it at 20 bucks while they keep missing payments and they keep diluting existing shareholders..they have really done a number on diluting the heck out of existing shareholders while they keep issuing themselves options and warrants that are in the money which hurt their bottom line tremendously....

To: CoffeePot who wrote (134)	7/14/1999 8:20:00 PM
From: Bo Didley	Read Replies (1) \| Respond to of 2557

SCIENCE OF THE COMMON COLD * * * * * * * * A major reason for the failure of medical science to find a cure for the common cold is the fact that the common cold can be caused by one of over 200 different viruses. This being the case, the standard medical paradigm of treating infectious ailments by vaccine has not been a viable option. It is known that the main portal of entry of the cold virus into the body is the cell lining of the nasal cavity. In the 1980's, it was discovered that the majority of the viruses responsible for the common cold all used a common entry point into the human body; the nasal cell ICAM-1 receptor. It was evident that if scientists could find a way to block the attachment of the cold viruses to the ICAM-1 receptors, a cure for the common would be at hand. In 1995, Dr. Charles B. Hensley and Dr. R. Steven Davidson (two of Gel Tech's founders) developed the ionic free flow emulsification technology which led to their discovery of the compound, ZinulloseTM, which blocks the ability of the cold virus from binding to the ICAM-1 binding sites and from infecting the nasal cells. Subsequently, Drs. Hensley and Davidson developed ZICAMTM, a cold remedy containing ZinulloseTM designed to reduce the duration of the common cold. Subsequent double blind research demonstrated that ZICAMTM is highly effective as a treatment for the common cold, reducing the duration of the cold from 10-14 days to an average of 1.5 days (Hensley and Davidson, 1998). zicam.com GUMM is the 60% owner of ZICAM.